



May 2009

Your link to the latest news on research, treatment, prevention and education from the state's only National Cancer Institute - designated Comprehensive Cancer Center

CINJ's YouTube Site Addresses Cancer Research and Survivorship

The Cancer Institute of New Jersey's (CINJ) recently updated YouTube site contains a number of informative videos about cancer survivorship including a discussion about the unmet needs of young cancer survivors from a public forum hosted by CINJ and the New Jersey Commission on Cancer Research. Visitors to the site can also find presentations from the 2008 Governor's Conference on Effective Partnering in Cancer Research: Genomics and Cancer Risk. You can access CINJ's YouTube site by visiting www.cinj.org and clicking on the YouTube logo.

CINJ Foundation Receives Grant from the Lance Armstrong Foundation for Survivorship Initiative

Receiving a boost from one of the nation's most highly recognized cancer foundations, The Cancer Institute of New Jersey will be able to expand a successful clinical program that meets the unique needs of cancer survivors. The Buildings and Bridges Program is being made possible by a \$100,000 Community Program grant from the Lance Armstrong Foundation, which seeks to inspire and empower people affected by cancer. The award was made recently to the CINJ Foundation. Through peer-based training, the Buildings and Bridges Program enhances the capacity of nurses, social workers and other healthcare providers to meet the practical and emotional needs of cancer survivors. It is an extension of CINJ's Center for Cancer Survivorship (CCS), a newly established entity serving as a focal point through which all survivorship research, clinical, educational, and advocacy efforts are coordinated. The aim of Buildings and Bridges Program is to build an understanding of cancer as a chronic disease that is survived, with ongoing practical and emotional impacts that can be managed. The award period runs for two years. It is anticipated the curriculum will be offered to 200 healthcare workers throughout New Jersey, during that time.

CINJ Researchers Look at FDA Approved Drugs to Target Early-Stage Prostate Cancer

The FDA-approved drugs Celebrex® and Lipitor® used respectively for arthritis pain and lowering one's cholesterol, are being tested by investigators at CINJ to see if they hold any promise in slowing or stopping the growth of prostate cancer when combined. The newly opened clinical trial is the result of recent laboratory study by Xi Zheng, PhD, MD, assistant research professor at Rutgers University, and CINJ member Allan Conney, PhD, director of Rutgers' Susan Lehman Cullman Laboratory for Cancer Research, who found that progression of stage one prostate cancer to stage two prostate cancer can be slowed through a combination of Celebrex® and Lipitor®. Susan Goodin, PharmD, FCCP, BCOP, associate director of clinical trials and therapeutics at CINJ and professor of medicine at UMDNJ-Robert Wood Johnson Medical School, is the lead investigator of this latest trial. Understanding the mechanism for tumor activation and growth may allow for targeting more specific tumor pathways for prostate cancer. Dr. Goodin notes by focusing on drugs that already have FDA approval, there is the potential to bring targeted therapies to patients faster than if a brand new compound or drug were being tested. Participants will take both drugs by mouth daily for six months and will have their PSA levels assessed every three months for the following two years. Adults with a diagnosis of prostate cancer and rising PSA levels but have no

evidence of prostate cancer are eligible to take part in the trial, although other criteria must be met. For additional information on how to participate, individuals should call 732-235-7251.



195 Little Albany Street • New Brunswick, NJ • Office of Communications 732/235-9891 • www.cinj.org

